Recent advances in chemotherapy for advanced gastric cancer

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 7

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

329

HTML

2180

Tables (1-3)

163

Sum=2672

Jul 15, 2010 (publication date) through Apr 26, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastrointest Oncol. Jul 15, 2010; 2(7): 287-294
Published online Jul 15, 2010. doi: 10.4251/wjgo.v2.i7.287

Table 3 Ongoing phase III clinical studies with monoclonal antibodies for gastric cancer

Study	Drug	Indication
ToGA^a[39]	XP or FP ± trastuzumab	Advanced gastric cancer (HER2-positive)
AVAGAST	XP ± bevacizumab	Advanced gastric cancer
REAL-3	EOX ± panitumumab	Advanced esophagogastric cancer
EXPAND	XP ± cetuximab	Advanced esophagogastric cancer
MAGIC-2	Perioperative ECX ± bevacizumab	Operable gastric cancer

^aCompleted trial.

Citation: Kim JG, Chung HY, Yu W. Recent advances in chemotherapy for advanced gastric cancer. World J Gastrointest Oncol 2010; 2(7): 287-294
URL: https://www.wjgnet.com/1948-5204/full/v2/i7/287.htm
DOI: https://dx.doi.org/10.4251/wjgo.v2.i7.287